Posted by Michael Wonder on 21 Sep 2018
Adverum Biotechnologies receives fast track designation for ADVM-022 gene therapy for the treatment of wAMD
19 September 2018 - ADVM-022 is a unique single-administration gene therapy delivered intra-vitreally for the treatment of wAMD.
Adverum Biotechnologies today announced the U.S. FDA has granted fast track designation for ADVM-022. ADVM-022 is a novel gene therapy candidate for the treatment of wet age-related macular degeneration (wAMD).
The multicentre, open-label, Phase 1, dose-escalation trial is designed to assess the safety and tolerability of a single intra-vitreal injection of ADVM-022 in patients with wAMD who are responsive to anti-vascular endothelial growth factor treatment.
